Description
GLYSIT PLUS 10/50 mg Film-Coated Tablets – 28’s
GLYSIT PLUS 10/50 mg Tablets combine Empagliflozin (10 mg), a selective SGLT2 inhibitor, and Vildagliptin (50 mg), a DPP-4 inhibitor, offering a dual mechanism of action for the effective management of type 2 diabetes mellitus.
Empagliflozin lowers blood glucose by increasing urinary glucose excretion, while Vildagliptin enhances the body’s natural incretin system, promoting glucose-dependent insulin secretion and suppressing glucagon levels. This fixed-dose combination helps target both fasting and postprandial blood glucose levels with a low risk of hypoglycemia.
GLYSIT PLUS is ideal for patients not adequately controlled on monotherapy and provides additional cardiovascular and renal protective benefits through Empagliflozin’s action. The pack of 28 tablets supports a convenient once-daily regimen for better treatment adherence.
Key Features:
-
Contains Empagliflozin 10 mg + Vildagliptin 50 mg per tablet
-
Dual mechanism: SGLT2 inhibition + DPP-4 inhibition
-
Effective in controlling fasting and post-meal blood glucose
-
Low risk of hypoglycemia and may support weight loss
-
Provides added heart and kidney protection in eligible patients
-
28 film-coated tablets for a 4-week supply
Usage:
Take once daily, with or without food, as directed by your physician. Regular monitoring of blood glucose and kidney function is advised.
Reviews
There are no reviews yet.